Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

FABP7 is a key metabolic regulator in HER2+ breast cancer brain metastasis.

Cordero A, Kanojia D, Miska J, Panek WK, Xiao A, Han Y, Bonamici N, Zhou W, Xiao T, Wu M, Ahmed AU, Lesniak MS.

Oncogene. 2019 Jul 19. doi: 10.1038/s41388-019-0893-4. [Epub ahead of print]

PMID:
31324889
2.

HIF-1α Is a Metabolic Switch between Glycolytic-Driven Migration and Oxidative Phosphorylation-Driven Immunosuppression of Tregs in Glioblastoma.

Miska J, Lee-Chang C, Rashidi A, Muroski ME, Chang AL, Lopez-Rosas A, Zhang P, Panek WK, Cordero A, Han Y, Ahmed AU, Chandel NS, Lesniak MS.

Cell Rep. 2019 Apr 2;27(1):226-237.e4. doi: 10.1016/j.celrep.2019.03.029.

3.

Local Application of Autologous Platelet-Rich Fibrin Patch (PRF-P) Suppresses Regulatory T Cell Recruitment in a Murine Glioma Model.

Panek WK, Pituch KC, Miska J, Kim JW, Rashidi A, Kanojia D, Lopez-Rosas A, Han Y, Yu D, Chang CL, Kane JR, Zhang P, Cordero A, Lesniak MS.

Mol Neurobiol. 2019 Jul;56(7):5032-5040. doi: 10.1007/s12035-018-1430-0. Epub 2018 Nov 20.

PMID:
30460615
4.

A Dendritic Cell-Targeted Adenoviral Vector Facilitates Adaptive Immune Response Against Human Glioma Antigen (CMV-IE) and Prolongs Survival in a Human Glioma Tumor Model.

Kim JW, Kane JR, Panek WK, Young JS, Rashidi A, Yu D, Kanojia D, Hasan T, Miska J, Gómez-Lim MA, Ulasov IV, Balyasnikova IV, Ahmed AU, Wainwright DA, Lesniak MS.

Neurotherapeutics. 2018 Oct;15(4):1127-1138. doi: 10.1007/s13311-018-0650-3.

PMID:
30027430
5.

Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma.

Pituch KC, Miska J, Krenciute G, Panek WK, Li G, Rodriguez-Cruz T, Wu M, Han Y, Lesniak MS, Gottschalk S, Balyasnikova IV.

Mol Ther. 2018 Apr 4;26(4):986-995. doi: 10.1016/j.ymthe.2018.02.001. Epub 2018 Feb 8.

6.

Hitting the nail on the head: combining oncolytic adenovirus-mediated virotherapy and immunomodulation for the treatment of glioma.

Panek WK, Kane JR, Young JS, Rashidi A, Kim JW, Kanojia D, Lesniak MS.

Oncotarget. 2017 Sep 11;8(51):89391-89405. doi: 10.18632/oncotarget.20810. eCollection 2017 Oct 24. Review.

7.

Multiplexed nanomedicine for brain tumors: nanosized Hercules to tame our Lernaean Hydra inside?

Panek WK, Khan OF, Yu D, Lesniak MS.

Nanomedicine (Lond). 2017 Oct 3. doi: 10.2217/nnm-2017-0260. [Epub ahead of print] No abstract available.

8.

Multiplexed RNAi therapy against brain tumor-initiating cells via lipopolymeric nanoparticle infusion delays glioblastoma progression.

Yu D, Khan OF, Suvà ML, Dong B, Panek WK, Xiao T, Wu M, Han Y, Ahmed AU, Balyasnikova IV, Zhang HF, Sun C, Langer R, Anderson DG, Lesniak MS.

Proc Natl Acad Sci U S A. 2017 Jul 25;114(30):E6147-E6156. doi: 10.1073/pnas.1701911114. Epub 2017 Jul 10.

9.

A Comparative Study of Replication-Incompetent and -Competent Adenoviral Therapy-Mediated Immune Response in a Murine Glioma Model.

Kim JW, Miska J, Young JS, Rashidi A, Kane JR, Panek WK, Kanojia D, Han Y, Balyasnikova IV, Lesniak MS.

Mol Ther Oncolytics. 2017 May 6;5:97-104. doi: 10.1016/j.omto.2017.05.001. eCollection 2017 Jun 16.

Supplemental Content

Loading ...
Support Center